Why the study?
Heart failure hospitalizations in the United States increased between 2013 and 2017, motivating a review of the best treatment options based on multiple articles.
What are the best treatment options for heart failure in 2023?
What are the best treatment options for heart failure in 2023?
This review reinforces the guideline recommendations for foundational quadruple medical therapy in HFrEF and the expanding indications for SGLT2 inhibitors across the ejection fraction spectrum.
Answers are grounded in this paper and cite their sources.
Rising US HF hospitalizations after 2012 merit clinical attention; leaves open causal factors for targeted investigation.
Congestive heart failure is a clinical condition in which the heart is unable to pump enough blood to meet the metabolic needs of the body because of pathological changes in the myocardium. The three main causes of CHF are coronary artery disease, diabetes mellitus, and hypertension. US hospitalizations for heart failure decreased up until 2012; however, from 2013 to 2017, an increase in HF hospitalizations was observed. In 2017, there were 1.2 million HF hospitalizations in the United States among 924 000 patients with HF. This represents a 26% increase in HF hospitalizations and number of patients hospitalized with HF. For this reason, as a team, we have decided to conduct a review of the best treatment options for heart failure based on multiple articles.
No takes yet. Share an insight, caveat, or question.
Santiago et al. (2023) conducted a review in Heart failure. Guideline-directed medical therapy (SGLT2 inhibitors, ARNIs, beta-blockers, MRAs) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: